Yearly zoledronic acid in postmenopausal osteoporosis.

Yearly zoledronic acid in postmenopausal osteoporosis.

Dades bibliogràfiques
Autors principals:	Poole, K, Kaptoge, S, Reeve, J
Format:	Journal article
Idioma:	English
Publicat:	2007

Ítems similars

EFFECT OF ZOLEDRONIC AND IBANDRONIC ACIDS ON BONE METABOLISM IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
per: O V Yakushevskaya, et al.
Publicat: (2012-08-01)

Treatment of postmenopausal osteoporosis, patient perspectives &ndash; focus on once yearly zoledronic acid
per: Raj Carmona, et al.
Publicat: (2009-07-01)

IDUA Gene Variants and Response to Zoledronic Acid Treatment in Chinese Women with Postmenopausal Osteoporosis
per: Lin H, et al.
Publicat: (2021-07-01)

Risk factors analysis in postmenopausal osteoporosis fragility fracture patients after treated with zoledronic acid
per: Ding Yue, et al.
Publicat: (2017-09-01)

Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis
per: Fernanda Martins Gazoni, et al.
Publicat: (2023-05-01)

Zoledronic acid does not slow spinal radiographic progression of osteoarthritis in postmenopausal women with osteoporosis and radiographic osteoarthritis
per: L.V. Host, et al.
Publicat: (2022-03-01)

Evaluating the Clinical Efficacy of Zoledronic Acid in the Prevention and Treatment of Osteoporosis in Postmenopausal Women, Compared with Conventional Medications
per: Fatemeh Rostami-Golmohammadi, et al.
Publicat: (2015-02-01)

Role of zoledronic acid in the prevention and treatment of osteoporosis
per: Räkel A, et al.
Publicat: (2011-03-01)

Zoledronic acid infusion for prevention and treatment of osteoporosis
per: John A Sunyecz
Publicat: (2010-10-01)

Zoledronic acid in the treatment of osteoporosis: indications for use
per: Nataliya Vladimirovna Toroptsova, et al.
Publicat: (2011-06-01)

Zoledronic acid in the treatment of osteoporosis: indications for use
per: Nataliya Vladimirovna Toroptsova, et al.
Publicat: (2011-06-01)

The Combination Therapy with Zoledronic Acid and Propranolol Improves the Trabecular Microarchitecture and Mechanical Property in an Rat Model of Postmenopausal Osteoporosis
per: Deepak Kumar Khajuria, et al.
Publicat: (2014-01-01)

The effects of zoledronic acid treatment on depression and quality of life in women with postmenopausal osteoporosis: A clinical trial study
per: Feyzi Gokosmanoglu, et al.
Publicat: (2016-01-01)

Management of osteoporosis in the aging male: Focus on zoledronic acid
per: Paul K Piper Jr, et al.
Publicat: (2009-06-01)

Cardiovascular Safety in Postmenopausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post‐Authorization Safety Study
per: Leslie Spangler, et al.
Publicat: (2023-10-01)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
per: Ruxu You, et al.
Publicat: (2022-03-01)

Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D
per: Federica Bellone, et al.
Publicat: (2021-11-01)

How zoledronic acid improves osteoporosis by acting on osteoclasts
per: Biao Wang, et al.
Publicat: (2022-08-01)

ZOLEDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS AND OTHER SKELETAL DISORDERS
per: S Yu Vorotnikova, et al.
Publicat: (2016-12-01)

Generic zoledronic acid for osteoporosis: focus on tolerability and safety
per: N. V. Toroptsova, et al.
Publicat: (2021-10-01)

Role of zoledronic acid in treatment of osteoporosis and prevention of fractures
per: A. V. Krivova, et al.
Publicat: (2022-01-01)

Zoledronate prevents bone loss after stroke
per: Poole, K, et al.
Publicat: (2006)

The effects of zoledronate on iliac bone remodelling in stroke patients
per: Poole, K, et al.
Publicat: (2007)

Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis
per: Ege Can Serefoglu, et al.
Publicat: (2010-05-01)

Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
per: Luca Dalle Carbonare, et al.
Publicat: (2010-08-01)

Once-yearly zoledronic acid 5 mg therapy for osteoporosis: a focus on a patient
per: Irina Aleksandrovna Baranova, et al.
Publicat: (2011-09-01)

Once-yearly zoledronic acid 5 mg therapy for osteoporosis: a focus on a patient
per: Irina Aleksandrovna Baranova, et al.
Publicat: (2011-09-01)

Preserving hip bone mineral density following stroke using intravenous zoledronic acid: Findings from a 1 year randomised controlled trial
per: Poole, K, et al.
Publicat: (2004)

Pathogenesis and treatment of postmenopausal osteoporosis
per: Milhaud, G, et al.
Publicat: (1983)

Effect of zoledronic acid on muscle metabolism in mice with osteoporosis combined with sarcopenia
per: Weilong Li, et al.
Publicat: (2024-11-01)

Annual Zoledronic Acid for the Treatment of Osteoporosis: A Randomized Controlled Trial
per: Asif Hussain, et al.
Publicat: (2023-01-01)

Zoledronic acid: challenges and pitfalls amid rehabilitation in primary osteoporosis and beyond
per: Alexandru Florin Florescu, et al.
Publicat: (2024-06-01)

Single Dose Therapy of Zoledronic Acid for the Treatment of Transient Osteoporosis of Hip
per: Sanjay Agarwala, et al.
Publicat: (2019-06-01)

Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients
per: Jun Xie, et al.
Publicat: (2019-12-01)

Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis
per: Johann D Ringe
Publicat: (2010-06-01)

Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture
per: Rol, et al.
Publicat: (2009-01-01)

EFFECT OF ZOLEDRONIC ACID THERAPY ON FRACTURE RISK IN THE TREATMENT OF MEN WITH OSTEOPOROSIS
per: Steven Boonen, et al.
Publicat: (2012-12-01)

Retrospective Study of the Effects of Zoledronic Acid on Muscle Mass in Osteoporosis Patients
per: Huang CF, et al.
Publicat: (2021-08-01)

The effects of zoledronate on iliac bone remodelling; a histomorphometric study in stroke patients
per: Poole, K, et al.
Publicat: (2007)

Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project
per: F. Bertoldo, et al.
Publicat: (2011-06-01)